List of Axid drug patents

Axid is owned by Braintree.

Axid contains Nizatidine.

Axid has a total of 1 drug patent out of which 1 drug patent has expired.

Expired drug patents of Axid are:

  • US6930119

Axid was authorised for market use on 25 May, 2004.

Axid is available in solution;oral dosage forms.

The generics of Axid are possible to be released after 17 July, 2022.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6930119 BRAINTREE Liquid pharmaceutical composition
Jul, 2022

(6 months ago)

Drugs and Companies using NIZATIDINE ingredient

Market Authorisation Date: 25 May, 2004

Treatment: NA

Dosage: SOLUTION;ORAL

How can I launch a generic of AXID before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in